Scholarlink

Background <p>Src homology 2 domain–containing protein tyrosine phosphatase 2 (SHP2) is a critical signaling molecule involved in tumor proliferation, invasion, metastasis, and immune evasion. In gastrointestinal (GI) cancers, however, its function is highly complex and context-dependent, varying across distinct cellular compartments within the tumor microenvironment (TME).</p> Main body <p>This review focuses on five major GI malignancies and reframes SHP2 function within a GI-specific TME, emphasizing how its roles are shaped by key environmental determinants—including cell type, tissue microenvironment, and disease state. We further discuss how current therapeutic modalities, such as chemotherapy, radiotherapy, and targeted therapy, modulate SHP2 activity and contribute to treatment resistance. In addition, we evaluate the therapeutic potential of SHP2 inhibition, highlighting recent advances in allosteric inhibitors, emerging combination strategies, and ongoing clinical studies.</p> Conclusions <p>Together, this review provides a conceptual framework for understanding SHP2 as both a signaling integrator and a precision therapeutic target in GI cancers, offering insights that may inform future mechanistic studies and the development of context-aware therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SHP2 as a pivotal modulator of the tumor microenvironment in gastrointestinal cancers: from mechanisms to targeted therapies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Sushan Wang,
  • Xiaoqing Zhao,
  • Jianhua Dong,
  • Jing Zhang,
  • Yuxin Wang,
  • Honglian Jin,
  • Xinyu Jiang,
  • Li Chen,
  • Ming Zhang,
  • Lei Ji,
  • Yawei Zhao

摘要

Background

Src homology 2 domain–containing protein tyrosine phosphatase 2 (SHP2) is a critical signaling molecule involved in tumor proliferation, invasion, metastasis, and immune evasion. In gastrointestinal (GI) cancers, however, its function is highly complex and context-dependent, varying across distinct cellular compartments within the tumor microenvironment (TME).

Main body

This review focuses on five major GI malignancies and reframes SHP2 function within a GI-specific TME, emphasizing how its roles are shaped by key environmental determinants—including cell type, tissue microenvironment, and disease state. We further discuss how current therapeutic modalities, such as chemotherapy, radiotherapy, and targeted therapy, modulate SHP2 activity and contribute to treatment resistance. In addition, we evaluate the therapeutic potential of SHP2 inhibition, highlighting recent advances in allosteric inhibitors, emerging combination strategies, and ongoing clinical studies.

Conclusions

Together, this review provides a conceptual framework for understanding SHP2 as both a signaling integrator and a precision therapeutic target in GI cancers, offering insights that may inform future mechanistic studies and the development of context-aware therapeutic strategies.